



**PHARMACEUTICALS EXPORT PROMOTION COUNCIL**  
(Set up by Ministry of Commerce & Industry, Govt., of India)

**COPY**

News / Story reproduced with thanks: Pharmaceutical Business Review

Dated: 1<sup>st</sup> Apr 2011

## Nile Therapeutics gets FDA fast track status for Cenderitide:

Nile Therapeutics has received the US Food and Drug Administration's (FDA) fast track designation for post-acute development program for Cenderitide.

Nile intends to develop Cenderitide as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from the hospital.

Nile CEO Joshua Kazam said they are very pleased that the FDA has recognized Cenderitide's potential to address an important unmet medical need for heart failure patients.

Direct link to the News/Story:

<http://regulatoryaffairs.pharmaceutical-business-review.com/news/nile-therapeutics-gets-fda-fast-track-status-for-cenderitide-310311>